STAT
APRIL 13, 2024
STAT publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay.
EMCrit Project
APRIL 13, 2024
10 heuristics for the new Crit Care doc from Ross Prager EMCrit Project by Scott Weingart, MD FCCM.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
APRIL 13, 2024
DEXILANT SOLUTAB (dexlansoprazole) Takeda pharms usa Patent: 8,784,885 Expiration: Apr 15, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact… Source
Pharmacy Times
APRIL 13, 2024
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses the role of the pharmacist in relation to bispecific care team readiness and patient readiness.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Patent Watch
APRIL 13, 2024
Annual Drug Patent Expirations for ADVAIR+HFA Advair Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from three suppliers.
Drug Patent Watch
APRIL 13, 2024
Annual Drug Patent Expirations for TYRVAYA Tyrvaya is a drug marketed by Oyster Point Pharma and is included in one NDA. It is available from one supplier.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Drug Patent Watch
APRIL 13, 2024
Annual Drug Patent Expirations for VOSEVI Vosevi is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier.
Drug Patent Watch
APRIL 13, 2024
Annual Drug Patent Expirations for RECORLEV Recorlev is a drug marketed by Strongbridge and is included in one NDA. It is available from one supplier.
Drug Patent Watch
APRIL 13, 2024
Annual Drug Patent Expirations for DAURISMO Daurismo is a drug marketed by Pfizer and is included in one NDA. It is available from one supplier.
Drug Patent Watch
APRIL 13, 2024
Annual Drug Patent Expirations for XOSPATA Xospata is a drug marketed by Astellas and is included in one NDA. It is available from one supplier.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Patent Watch
APRIL 13, 2024
This chart shows the pharmaceutical companies with the most cream dosed drugs. For a different perspective, see the most popular dosage types.
Expert insights. Personalized for you.
266 
Let's personalize your content